General population norms for the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

摘要: BACKGROUND: Metastatic renal cell cancer is associated with poor long-term survival and has no cure. Traditional clinical endpoints are best supplemented by patient-reported outcomes designed to assess symptoms function. Normative data was obtained on the National Comprehensive Cancer Network-Functional Assessment of Therapy–Kidney Symptom Index (NFKSI) aid in score interpretation planning future trials. METHODS: General population were from 2000 respondents, who completed 19-item NFKSI-19, as well SF-36 (Short Form 36-item instrument) PROMIS-29 (29-item Patient Reported Outcomes Measurement Information System), both general health status measures. Basic demographic self-reported comorbidity also collected. RESULTS: The sample 50% female, 85.7% caucasian, an equal distribution across age bands 18 years 75 older. Most respondents (62.8%) had more than a high school education reported Eastern Cooperative Oncology Group performance normal activity without (63.4%). Score distributions its subscales, individual items summarized. CONCLUSIONS: The NFKSI-19 subscales now have scores for US population, allowing comparability generic questionnaires such PROMIS-29. These can be used guide treatment expectations plan comparative effectiveness research using scales. 2013. © 2012 American Society.